Arvinas Says Investigational New Drug Application For ARV-393 Has Been Authorized By FDA

-3.57%

Arvinas

ARVN

11.90

-3.57%

Also, the clinical trial application submitted by the Company for ARV-102, the Company’s PROTAC® degrader designed to target the LRRK2 protein, has been authorized by European Medicines Agency. The Company plans to initiate first-in-human Phase 1 clinical trials for both ARV-393 and ARV-102 in the first half of 2024.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.